These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33914406)

  • 21. Anti-factor VIII inhibitor alloantibodies recognizing the A2 domain in the human factor VIII heavy chain poorly bind to porcine factor VIII.
    Sawamoto Y; Shima M; Tanaka I; Nakai H; Kamisue S; Scandella D; Yoshioka A
    Int J Hematol; 1997 Feb; 65(2):151-8. PubMed ID: 9071819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of anti-factor VIII antibody levels in patients with haemophilia A receiving immune tolerance induction therapy or bypassing agents.
    Boylan B; Niemeyer GP; Werner B; Miller CH
    Haemophilia; 2021 Jan; 27(1):e40-e50. PubMed ID: 33216433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A ROTEM method using APTT reagent and tissue factor as the clotting activators may better define bleeding heterogeneity in moderate or severe haemophilia A (part I: Study in plasma samples).
    He S; Eelde A; Petrini P; Wallen H; Gabrielsson L; Svensson J; Blombäck M; Holmström M
    Thromb Res; 2018 Nov; 171():7-13. PubMed ID: 30216822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody response to recombinant human coagulation factor VIII in a new rat model of severe hemophilia A.
    Lövgren KM; Søndergaard H; Skov S; Weldingh KN; Tranholm M; Wiinberg B
    J Thromb Haemost; 2016 Apr; 14(4):747-56. PubMed ID: 26784374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined FV and FVIII deficiency.
    Spreafico M; Peyvandi F
    Haemophilia; 2008 Nov; 14(6):1201-8. PubMed ID: 19141160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of zebrafish coagulation cofactors Fviii and Fv mutants and modeling hemophilia A and factor V deficiency.
    Dhinoja S; De Maria A; Qaryoute AA; Jagadeeswaran P
    Blood Coagul Fibrinolysis; 2024 Jul; 35(5):238-247. PubMed ID: 38874909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab.
    Nogami K; Matsumoto T; Tabuchi Y; Soeda T; Arai N; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jun; 16(6):1078-1088. PubMed ID: 29645406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retrospective examination of coagulation parameters in 33 patients with autoimmune coagulation factor deficiencies in Japan: A single-center analysis.
    Osaki T; Souri M; Ogawa Y; Sato H; Mitsui T; Ichinose A
    Thromb Res; 2022 May; 213():154-162. PubMed ID: 35378421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of FVIII Inhibitors Among Children with Hemophilia A: Experience at the Jordanian Royal Medical Services.
    Oudat R; Al-Maharmeh M; Al-Ghrayeb R; Ogeilat T; Mustafa MK
    Med Arch; 2020 Jun; 74(3):187-190. PubMed ID: 32801433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hydrolysis of factor VIII mediated by catalytic antibodies occurs in haemophilia A patients with or without factor VIII inhibitors.
    Grosbois SS; Brionne MF; de Longcamp AL; Gautier P; V Kaveri S; Borel-Derlon A; Repessé Y
    Haemophilia; 2013 Mar; 19(2):322-9. PubMed ID: 23216758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activated protein C has a regulatory role in factor VIII function.
    Wilhelm AR; Parsons NA; Samelson-Jones BJ; Davidson RJ; Esmon CT; Camire RM; George LA
    Blood; 2021 May; 137(18):2532-2543. PubMed ID: 33512448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Screening and analysis of coagulation factor VIII inhibitor in patients with hemophilia A].
    Zhang AL; Yang LH; Liu XE; Zhao H; Zhang JH; Dong CX; Qi XL; Qin XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):968-70. PubMed ID: 21867625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice.
    Baumgartner CK; Mattson JG; Weiler H; Shi Q; Montgomery RR
    J Thromb Haemost; 2017 Jan; 15(1):98-109. PubMed ID: 27496751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Usefulness of chromogenic assays for potency assignment and recovery of plasma-derived FVIII and FIX concentrates or their recombinant long acting therapeutic equivalents with potential application in treated pediatric hemophiliac patients.
    Amiral J; Seghatchian J
    Transfus Apher Sci; 2018 Jun; 57(3):363-369. PubMed ID: 29895509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune Responses to Plasma-Derived Versus Recombinant FVIII Products.
    Peyvandi F; Miri S; Garagiola I
    Front Immunol; 2020; 11():591878. PubMed ID: 33552050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01/2010 study.
    Werwitzke S; Geisen U; Nowak-Göttl U; Eichler H; Stephan B; Scholz U; Holstein K; Klamroth R; Knöbl P; Huth-Kühne A; Bomke B; Tiede A
    J Thromb Haemost; 2016 May; 14(5):940-7. PubMed ID: 26988717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cross-reacting recombinant porcine FVIII inhibitors in patients with acquired haemophilia A.
    Bowyer A; Shepherd F; Platton S; Guy S; Kitchen S; Maclean R
    Haemophilia; 2020 Nov; 26(6):1181-1186. PubMed ID: 32997894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.
    Beckman JD; Holle LA; Wolberg AS
    J Thromb Haemost; 2018 Jan; 16(1):131-141. PubMed ID: 29080382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factor VIII inhibitor development in Egyptian hemophilia patients: does intron 22 inversion mutation play a role?
    Sherief LM; Gaber OA; Youssef HM; Sherbiny HS; Mokhtar WA; Ali AAA; Kamal NM; Abdel Maksoud YH
    Ital J Pediatr; 2020 Sep; 46(1):129. PubMed ID: 32928254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors.
    Luna-Záizar H; Beltrán-Miranda CP; Esparza-Flores MA; Soto-Padilla J; Bergés-García A; Rodríguez-Zepeda MD; Pompa-Garza MT; Jaloma-Cruz AR
    Haemophilia; 2014 Jan; 20(1):e7-14. PubMed ID: 24354488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.